Drug Trial Radar · NCT07591168
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, non-randomized Phase Ib/II clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BL-M11D1 for injection in patients with relapsed/refractory myelodysplastic syndromes.
Conditions
- Myelodysplastic Syndromes
Interventions
BL-M11D1Drug
Administration by intravenous infusion for a cycle of 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
- Phase Ib: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
- Phase II: Objective Response Rate (ORR)Time frame: Up to approximately 24 months
- Phase II: Complete Response (CR)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.